Table 4: Result of sensitivity analysis.

VariablePatients (rifaximin/control)Pooled RR

All in Europe [2429]231 (113/118)3.16 [0.92, 10.93]0.07
Acute HE [21, 27, 30]157 (82/75)0.77 [0.20, 2.93]0.70
Chronic HE [26, 28, 29]107 (54/53)7.6 [1.87, 30.78]0.005

HE: hepatic encephalopathy; control lactulose or lactitol; RR: relative risk.